Background {#Sec1}
==========

Hepatitis C virus (HCV) infection is now considered to be of significant global health importance affecting all countries and requires the needed attention \[[@CR1]\]. About 2.8 % of the world's population representing almost 180 million individuals are estimated to be infected with HCV; as much as 80 % of this number suffer chronic infection---almost five times the number for HIV \[[@CR2]\]. Although, recent estimates point to a declining burden mainly due to reduced prevalence among children, it is widely accepted that more needs to be done to control the disease \[[@CR3]\].

Chronic HCV infection has been strongly implicated in the development of hepatocellular carcinoma (HCC). About 10--20 % of chronic HCV sufferers develop liver cirrhosis within 20--30 years of onset of infection, 1--5 % of these are likely to progress into liver cancer \[[@CR4], [@CR5]\]. Each year, more than 350,000 deaths from HCV-related liver diseases are recorded across the globe with majority of these deaths arising from liver cirrhosis and HCC \[[@CR6]\]. Over 25 % of the global cases of liver cirrhosis and HCC are attributable to chronic HCV infection, with rates higher in endemic regions \[[@CR7]\].

There are variations in the burden of HCV across the globe as depicted by prevalence rates of 1.5 %, 2.3 % and 3.2 % for the World Health Organization (WHO)'s Americas, Europe and Africa regions, respectively \[[@CR1]\]. Madhava et al. \[[@CR8]\] estimated the HCV prevalence in 2002 in Sub-Saharan Africa to be 3.0 % with a prevalence rate of 2.4 % for the West African region where Ghana is located. Recent estimate by Rao et al. \[[@CR9]\] presents a slightly lower prevalence of 2.65 % for the Sub-Saharan Africa region.

However, there are concerns that prevalence rates reported for Sub-Saharan Africa may be substantially underestimated owing to factors such as the limited availability of HCV representative surveys in the region \[[@CR10]\]. Aside the regional variations in HCV prevalence, even within countries, the patterns of HCV epidemiology vary greatly. In the United States for instance, highest HCV prevalence is recorded among persons 30-49 years, although in countries like Italy and China, persons \>50 years account for most infections \[[@CR11]\].

It is important to highlight that there are some real challenges in documenting an accurate burden of HCV to ascertain true incidence and prevalence in any country. Such challenges include for instance, the unavailability of assays with ability to distinguish acute and chronic infections as majority of acute HCV infections often present no symptoms \[[@CR12]\].

Globally, where the impact of HCV has been thoroughly studied, the implications on national health systems has been found to be enormous \[[@CR13]\]. Razavi et al. \[[@CR14]\] estimated the lifetime cost of a person infected with HCV in 2011 in US to be at \$64,490, although, this could rise to \$205,760 (\$154,890--\$486,890) when medical inflation is applied. Myer et al. \[[@CR15]\] also estimated an amount of \$64,694 as the lifetime cost for Canadian with HCV infection in 2013 which could rise to as high as \$327,608 if liver transplantation becomes necessary.

Viral hepatitis including HCV, are considered to be significant contributors to morbidity and mortality in Ghana and deserve greater attention \[[@CR16]\]. However, extensive aggregate data on prevalence of HCV in Ghana are currently lacking \[[@CR17]\]. Lavanchy \[[@CR1]\] reported a national HCV prevalence rate of 1.7 % for Ghana in 2010 based on WHO's data. A systematic review focusing on HCV seroprevalence in Africa by Riou et al. \[[@CR18]\] also reported an HCV prevalence rate for Ghana within the range 0.2--9.4 %. Aside the very wide range presented by this study, the estimate was also based on only ten studies and was restricted to adult populations. To the best of our knowledge, no other thoroughly conducted systematic review and meta-analysis on the prevalence of chronic HCV infection in Ghana has been published. This observation further highlight the lack of thorough compilation of the evidence regarding the prevalence of HCV in Ghana.

To inform evidence-based policymaking, public health research and programming prioritization in Ghana, accurate prevalence estimates based on thorough and up-to-date evidence complication is essentially needed. In this paper, we aimed at estimating the prevalence of chronic HCV infection in Ghana based on studies published over the last two decades (1995--2015). This was a contribution to our large study documenting the burden of common viral hepatitis in Ghana.

Methods {#Sec2}
=======

This review was conducted in accordance with recommendations outlined in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement \[[@CR19]\].

Search strategy {#Sec3}
---------------

We conducted searches in PubMed, Science Direct, Google scholar, Africa Journals Online (AJOL) and the WHO African Index Medicus databases to identify entries on HCV prevalence in Ghana up to 31^st^ December 2015. The key words used were Hepatitis C, prevalence and Ghana and similar terms such as HCV and anti-HCV were crossed. The main limits used were 'Humans' and 'English'. The specific search sequence for PubMed are as follows; (("hepatitis c"\[MeSH Terms\] OR "hepacivirus" \[MeSH Terms\] OR Hepatitis C \[Text Word\] OR "hepatitis c antibodies"\[MeSH Terms\] OR anti-HCV \[Text Word\] OR HCV \[All Fields\])) AND ("prevalence" \[MeSH Terms\] OR prevalence \[Text Word\])) AND ("ghana" \[MeSH Terms\] OR ghana\[Text Word\])).

We also searched the websites of the ministry of health (<http://www.moh-ghana.org/>) and Ghana Health service (<http://www.ghanahealthservice.org/>) for non-indexed studies or reports on the subject. Cross-checking of bibliographies from other published reviews and from all retrieved articles was conducted to identify additional publications.

Studies inclusion criteria {#Sec4}
--------------------------

We included only primary studies published in English between January 1995 and December 2015 and which reported chronic HCV prevalence information among Ghanaians. This period was considered as we were primarily interested in looking at HCV prevalence over the last two decades. For a study to be included, the diagnosis of HCV should have been based on serological assays that detect antibodies to HCV; or molecular assays that aim to detect, quantify, and/or characterize HCV-RNA genomes \[[@CR20]\]. No age restrictions were imposed and we considered studies conducted in both children and adults.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two reviewers (RO, AA) screened titles and abstracts against predefined study inclusion criteria. Full-text articles were also independently screened by the same reviewers (AA, RO) for eligibility. Quality appraisal of studies were carried out using a 12-point scoring system modified from the Downs and Black checklist as adopted in similar reviews \[[@CR21], [@CR22]\]. The criteria included for instance, whether study's objective was clearly defined, study design clearly described, whether participants were described (e.g. blood donors, IDUs) and are representative of general population and whether ample sample size was adequate. Additionally, other measures such as whether studies accounted for missing data, cofounders discussed, and whether socioeconomic variables such as age, gender, setting (e.g. urban or rural) were fully described. Attention was also paid to whether studies reported methods by which HCV status were determined and whether the outcomes of interest were clearly spelt out and any biases reported. Studies were graded according to their scores into high, medium or low. We collected further descriptive information such as author details, study's publication year, region of Ghana and the reported HCV prevalence. Prevalence data were independently extracted by AA and AM and crosschecked by RO. Any discrepancies were resolved through consensus-based discussions.

Data analysis {#Sec6}
-------------

We conducted a meta-analysis using Open Meta (analyst) software, an open-source, cross-platform software for advanced meta-analysis \[[@CR23]\] and StatsDirect statistical software (Version 3.0.0, StatsDirect Ltd, Cheshire UK) \[[@CR24]\]. The pooled and individual study proportions were assessed at 95 % confidence interval. We tested for heterogeneity based on Cohran's Q statistic test and degree of inconsistency (I^*2*^) \[[@CR25]\]. An I^2^ \> 50 % was considered as representing meaningful heterogeneity. In this case, the random effect model (DerSimonian-Laird) was adopted over fixed effect model in the analysis of pooled effects \[[@CR25]\]. We carried out direct observation of funnel plots to detect presence of publication bias and this was confirmed with Egger and Harbord statistics tests \[[@CR26], [@CR27]\]. A leave-one-out sensitivity analysis was carried out to assess the impact of each study on the overall pooled estimate \[[@CR28]\]. Sub-analysis was carried out for different study periods as well as for specific populations (e.g. HIV patients, blood donors etc.) and regions of Ghana. In all computations, statistical significance was set at *p* \< 0.05.

Results {#Sec7}
=======

Studies identification and characteristics {#Sec8}
------------------------------------------

Figure [1](#Fig1){ref-type="fig"} summarises the studies retrieval steps. A total of 874 citations were retrieved from the searches. Following, titles and abstract screening, removal of duplicate, and full-text analysis and referencing screening, 24 studies met the inclusion criteria for inclusion in the overall analysis \[[@CR17], [@CR29]--[@CR51]\]. The 24 studies (Table [1](#Tab1){ref-type="table"}) which were conducted in nine regions of Ghana altogether involved a sample size of 100,782. The regional distribution of studies were, Ashanti (12), Greater Accra (6), Northern (1), Brong-Ahafo (1), Central (1), Upper East (1) and two (2) multi-regional studies. Majority of the studies (87.5 %, *n* = 21) were conducted among urban residents. According to publication years, 25 % (*n* = 6), 33 % (*n* = 8) and 42 % (*n* = 10) of studies were published within the periods 1995--2002, 2003--2009 and 2010--2015 respectively. Sample sizes across the 24 studies ranged from 110 to 51,100. A significant proportion (54 %, *n* = 13) of the studies were conducted among blood donors (either replacement or voluntary donors) participants. Only one study was specifically conducted in children \[[@CR44]\]. Three studies were conducted among specific disease group of patients (diabetes and HIV). The quality appraisal scores graded 4 %, 38 % and 58 %, of studies to be of low, medium and high quality, respectively.Fig. 1A PRISMA flow chart of studies' retrieval stepsTable 1Descriptive characteristics of studies reporting chronic HCV prevalence in GhanaStudy NoAuthor detailsYear of publicationDesignRegion of studyStudy populationAge group (yrs.)SettingSample size (n)MethodAnti-HCV (%)Quality grade1Acquaye and Tetteh-donkor. \[[@CR29]\]2000Cross-sectionalGreater AccraBlood donors^€^n.sUrban1300ELISA5.2Medium2Adoba et al. \[[@CR30]\]2015Cross-sectionalAshantiBarbers28.18^a^urban200Rapid test0.5High3Adjei et al. \[[@CR31]\]2006Cross-sectionalEastern & Greater AccraPrison inmates & Officers17--84Urban363ELISA20.1High4Adjei et al. \[[@CR32]\]2008Cross-sectionalNational (Excludes Upper East & West)Prison Officers38.1^b^Urban445ELISA18.7High5Allain et al. \[[@CR33]\]2009Cross-sectionalAshantiBlood donors^€^\>16Urban51100Rapid test0.4High6Allain et al. \[[@CR34]\]2010Cross-sectionalAshantiBlood donors^€^31.0^a^Urban11000Rapid test0.22High7Amidu et al. \[[@CR35]\]2010Cross-sectionalUpper EastBlood donors^€^17-58Urban4146Rapid test3.6Medium8Ampofo et al. \[[@CR17]\]2002Cross-sectionalGreater AccraBlood donors^€^16-60Urban808Agglutination assay8.4High9Apea-Kubi et al. \[[@CR36]\]2006Cross-sectionalGreater AccraPregnant & non-pregnant women29.6^a^Urban517Rapid test5.2High10Blankson et al. \[[@CR37]\]2005Case-controlGreater AccraCirrhotic & non-cirrhotic patients15--90Urban350ELISA4.3High11Candotti et al. \[[@CR38]\]2001Cross-sectionalAshantiBlood donors^€^32^a^Urban2738EIA1.3High12Candotti et al. \[[@CR39]\]2003Cross-sectionalAshantiBlood donors^€^29^a^Urban4984EIA1.3Medium13Ephraim et al. \[[@CR40]\]2014Cross-sectionalCentralDiabeticsn.sUrban110Rapid test0.0Medium14Ephraim et al. \[[@CR41]\]2015Cross-sectionalAshantiPregnant women10--40Urban168Rapid test7.7Medium15King et al. \[[@CR42]\]2014Cross-sectionalAshantiHIV+ individualsn.sUrban408Plasma assay1.0High16Kubio et al. \[[@CR43]\]2012Register ReviewNorthernBlood donors^€^n.sRural819n.s6.1Low17Lassey et al. \[[@CR44]\]2004Cross-sectionalGreater AccraParturientsn.sUrban638ELISA2.5Medium18Martinson et al. \[[@CR45]\]1996Cross-sectionalAshantiChildren6--18rural803n.s5.4Medium19Nkrumah et al. \[[@CR46]\]2011Cross-sectionalAshantiBlood donors^€^26--35Rural2773Rapid test5.63Medium20Owusu-Ofori et al. \[[@CR47]\]2005Cross-sectionalAshantiBlood donors^€^n.sUrban9372Rapid test0.5High21Sagoe et al. \[[@CR48]\]2012Cross-sectionalGreater AccraHIV+ individuals≥18Urban138Plasma assay3.6High22Sarkodie et al. \[[@CR49]\]2001Cross-sectionalAshantiBlood donors^€^16--52Urban3264Mixed methods1.6High23Walana et al. \[[@CR50]\]2014Cross-sectionalBrong-AhafoBlood donors^€^20--49Urban3402ICT4.4Medium24Wansbrough-Jones et al. \[[@CR51]\]1998Cross-sectionalAshantiPregnant women & blood donors^€^15--60Urban936ELISA2.8High*n.s* not specified, *ICT* immunochromatography, *ELISA* enzyme-linked immunosorbent assay, *EIA* enzyme immunoassays, *anti-HCV* hepatitis C antibody^a^average^b^median^€^Blood donors is used to represent either voluntary or replacement donors or both

Overall national prevalence {#Sec9}
---------------------------

The reported anti-HCV prevalence rate across the 24 studies ranged from 0 % to 20.1 %. In 63 % (15/24) of studies, the reported prevalence was more than 2 %--- the level at which anti-HCV prevalence rate is considered to be high \[[@CR52]\]. 42 % of studies reported prevalence rates at least 200 % higher than the 2 % level. The pooled national prevalence estimate (Fig. [2](#Fig2){ref-type="fig"}) was determined as 3.0 % (95 % CI = 2.6 % to 3.5 %). The result of heterogeneity (*I*^*2*^) was also 97.61 % (*p* \< 0.001) for the degree of inconsistency.Fig. 2Forest plot of studies reporting chronic HCV infection prevalence in Ghana

Blood donors {#Sec10}
------------

A total of thirteen (13) studies involved blood donor participants (voluntary and family replacement donors), although data on anti-HCV prevalence for this specific population obtained from twelve (12) studies. The 12 studies altogether involved a sample size of 95,706. The reported HCV prevalence was in the range of 0.22 to 8.4 %. The pooled estimate of HCV prevalence among blood donors (Fig. [3](#Fig3){ref-type="fig"}) across the twelve (12) studies was 2.6 % (95 % CI = 2.1 % to 3.1 %). The result of heterogeneity (*I*^*2*^) was also 98.33 % (*p* \< 0.001) for the degree of inconsistency. Separate prevalence for VBDs and RBDs were retrieved from five studies \[[@CR34], [@CR38], [@CR43], [@CR47], [@CR49]\]. The pooled prevalence of HCV prevalence rate for VBDs was determined as 0.3 % (95 % CI 0.1--0.5 %). The result of heterogeneity (*I*^*2*^) was also 69.04 % (*p* \< 0.0001) for the degree of inconsistency. On the other hand, the pooled HCV prevalence for RBDs was determined as 1.8 % (95 % CI 0.9--2.6 %). The result of heterogeneity (*I*^*2*^) was determined as 95.42 % (*p* \< 0.001). The prevalence difference of 1.5 % (95 % CI 1.3--1.8 %) between RBDs and VBDs was found to be statistically significant (*p* \< 0.0001).Fig. 3Forest plot of studies reporting chronic HCV prevalence among blood donors in Ghana

Pregnant women and parturients {#Sec11}
------------------------------

Four studies involved pregnant women and parturient participants \[[@CR36], [@CR41], [@CR44], [@CR51]\]. One of these studies \[[@CR51]\], did not present any specific prevalence data on pregnant women and thus was excluded from this analysis. Hence anti-HCV prevalence among pregnant women and parturients were retrieved from three studies which together involved a total of 1,100 participants. The HCV prevalence across these studies was within the range 2.5 to 7.7 %. The pooled HCV prevalence estimate for the pregnant women and parturients was determined as 4.6 % (95 % CI = 1.8 % to 7.5 %) (Fig. [4](#Fig4){ref-type="fig"}). The result of heterogeneity (*I*^*2*^) was determined as 75.74 % (*p* = 0.016) for the degree of inconsistency.Fig. 4Forest plot of studies reporting chronic HCV prevalence amongst pregnant women and parturients in Ghana

High risk groups {#Sec12}
----------------

Persons at greater risk of chronic HCV include injection drug users (IDUs), HIV patients, people in custodial settings and commercial sex workers \[[@CR53]--[@CR55]\]. Two studies \[[@CR31], [@CR32]\] were conducted in prisons although data among prisoners was retrieved from only one study \[[@CR31]\]. An extremely high (19.2 %) prevalence of HCV was recorded among the incarcerated persons. Reported illegal drug use was high among this group (83.2 % reporting using marijuana, 7.3 % reported cocaine use, 5.2 % indicate history of heroin abuse and 4.2 % used phencyclidine) \[[@CR31]\]. Prevalence of HCV among HIV positive individuals was retrieved from three studies \[[@CR42], [@CR43], [@CR48]\]. The pooled prevalence of chronic HCV among HIV patients from the three studies was determined as 2.8 % (95 % CI = 0.4--6 %). The result of heterogeneity (*I*^*2*^) was determined as 65.86 % (*p* = 0.0053) for the degree of inconsistency. No study reported individual prevalence rate among IUDs as well as for commercial sex workers.

HCV prevalence for rural and urban settings {#Sec13}
-------------------------------------------

Three (3) studies were conducted among rural dwellers \[[@CR43], [@CR45], [@CR46]\]. These studies involved a total of 4,395 participants and reported individual HCV prevalence ranging from 5.4 to 6.1 %. The pooled HCV prevalence estimate for urban setting was determined as 5.7 % (95 % CI 5.0--6.3 %; I^2^ = 0; *p* = 0.804). Twenty-one (21) studies involved urban dwellers and together included a total of 96,387 participants. The reported individual HCV prevalence ranged from 0 to 20.1 %. The pooled prevalence estimate (Fig. [5](#Fig5){ref-type="fig"}) for the studies conducted in urban settings was 2.6 % (95 % CI = 2.1 % to 3.0 %). The result of heterogeneity (*I*^*2*^) was determined as 97.3 % (*p* = 0.001) for the degree of inconsistency. The difference in pooled HCV prevalence estimates for rural and urban settings was statistically significant (*p* \< 0.002).Fig. 5Forest plot of HCV infection for studies conducted in urban and rural parts of Ghana

Regional prevalence {#Sec14}
-------------------

Pooled HCV prevalence estimate for the Ashanti region was estimated from 13 studies which altogether involved 87,805 participants. The reported HCV prevalence rates across the thirteen (13) studies ranged from 0.22 to 11.9 %. The pooled HCV prevalence estimate for Ashanti region was determined as 1.5 % (95 % CI = 1.2 to 1.9 %; I^2^ = 96.24; *p* \< 0.001). Pooled HCV prevalence for the Greater-Accra Region, was estimated from eight studies which altogether involved 4,063 participants. The reported individual HCV prevalence from the eight studies ranged from 2.5 to 17.8 %. The pooled HCV prevalence for the Greater-Accra region was determined as 6.4 % (95 % CI = 4.2 % to 8.6; I^2^ = 88.5 %; *p* \< 0.001). We were unable to deduce aggregate data for Eastern, Upper East, Brong-Ahafo, Central, Northern, Western and Volta regions due to limited number of studies and no single reported data was available for Upper West region (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6A map of chronic HCV prevalence across regions of Ghana

HCV prevalence according to periods in which studies were conducted {#Sec15}
-------------------------------------------------------------------

Studies were grouped according to the mid-year of the period in which they were undertaken. The four period groupings were 1995--2000, 2001--2005, 2006--2010 and 2011--2015. Among the seven studies conducted within the period 1995--2000 which involved a total 14,833 participants, the reported individual HCV prevalence ranged from 1.3 to 8.4 %. The pooled HCV prevalence estimates for the studies conducted in the period 1995--2000 was 3.4 % (95 % CI 2.3 to 4.4 %; I^2^ = 94.76; *p* \< 0.001). The seven studies conducted within the period 2001--2005 also involved a sample population of 15,831 and reported HCV prevalence within the range of 0.5--20.5 %. The pooled HCV prevalence estimate for the studies conducted in the period 2001--2005 was determined as 6.9 % (95 % CI 4.4 to 9.4 %; I^2^ = 98.16; *p* \< 0.001). Five studies were conducted in the period 2006--2010 and together involved 65,830 participants and reported HCV prevalence ranging from 0.2 to 6.1 % with a pooled HCV prevalence estimate of 2.0 % (95 % CI 1.4--2.6 %; I^2^ = 98.08; *p* \< 0.001). Among the five studies conducted within the period 2011--2015 which altogether involved a total of 14,833 participants, the reported HCV prevalence ranged from 1.3 to 8.4 %. The pooled estimate for the studies conducted in the period 2011--2015 was 2.4 % (95 % CI =0.3 to 4.5 %; I^2^ = 94.42; *p* \< 0.001). Hence the order of ascending HCV infection prevalence rates according to years in which studies were conducted was 2006--2010 \< 2011--2015 \< 1995--2002 \< 2001--2005 (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7HCV infection prevalence according to periods in which studies were conducted

Heterogeneity assessment {#Sec16}
------------------------

A direct observation of funnel plot revealed an asymmetrical display of the HCV prevalence reported by the various studies (Fig. [8](#Fig8){ref-type="fig"}). The presence of publication bias was confirmed by statistically significant Egger (*p* \< 0.0001) and Harbord (*P* = 0.0002) tests. A leave-one-out analysis which was performed to assess the impact of the various studies on the pooled estimates \[[@CR32]\], showed that the pooled HCV prevalence estimate was dominated by Allain et al. \[[@CR37]\] and Allain et al. \[[@CR38]\]. The most dominant studies all involved blood donors (Fig. [9](#Fig9){ref-type="fig"}).Fig. 8A funnel plot of studies reporting chronic HCV infection prevalence in GhanaFig. 9A leave-one-out sensitivity plot of studies reporting chronic HCV infection prevalence in Ghana

Discussion {#Sec17}
==========

In this review, we present a high prevalence (3.0 %) of chronic HCV infection in Ghana. This prevalence rate is significantly higher than the national prevalence of 1.7 % reported previously by Lavanchy \[[@CR1]\]. The observation of higher prevalence rate in this study may be in alignment with the observation by Layden et al. \[[@CR10]\] that HCV prevalence rates for sub-Saharan Africa have generally been underestimated in the past. Even that, the prevalence rate reported may still be modest considering that a significant proportion of studies included in this review involved low risk populations such as blood donors who are often biased towards a healthier population \[[@CR56]\]. Additionally, as highlighted in the sensitivity analysis, the anti-HCV prevalence was most impacted by two studies all conducted in blood donors \[[@CR37], [@CR38]\]. In developed countries like Australia and the US, prevalence of chronic HCV infection has been estimated to be less than 2 % \[[@CR7]\]. This may highlight that the level of chronic HCV infection in Ghana may be considerably high.

The high prevalence of chronic HCV infection together with previously reported high prevalence of other viral hepatitis in Ghana \[[@CR57]\], points to a growing concern regarding the safety of blood products in the country. Although, Ghana has a national blood policy which requires that all donated blood are screened for blood-borne infections including HIV 1 and 2, Hepatitis B (HBV), HCV and Syphilis \[[@CR58]\], a greater emphasis and stricter monitoring to ensure high levels of adherence to this policy will be needed to minimise the risk of supplying contaminated blood to patients.

The prevalence of chronic HCV infection among pregnant women was estimated as 4.6 % which is high when reference is made to other regions like the United States and Europe where prevalence of chronic HCV among this group has been estimated to be around 1--2.5 % \[[@CR59]\]. Our result therefore highlight the importance of vertical transmission in the overall spread of HCV infection in Ghana. Studies have demonstrated that chronic HCV infection during pregnancy poses significant risks to mother and child and may further exacerbate the risks of preterm delivery, low birth weight, congenital malformations, glucose intolerance during pregnancy and overall perinatal mortality \[[@CR60], [@CR61]\]. The high HCV prevalence among pregnant women draws attention to the need for the adoption of a national program that includes HCV screening for all or most-at-risk pregnant women in Ghana. Although, a vaccine to prevent HCV infection is currently non-existent, treatment with preparations such as interferon for women with high HCV viral load will lead to reduction in HCV infection levels for the women and also minimise the risks of vertical transmission of the disease in future pregnancies \[[@CR59]\].

Several factors may contribute to the observed high levels of chronic HCV infection in Ghana. Studies have reported low levels of awareness and knowledge among Ghanaians about the transmission pathways of the disease. For instance, Mutocheluh and Kwarteng \[[@CR62]\], reported that among 200 barbers in Kumasi none (0 %) of the barbers could describe the common HCV transmission pathways and only 7 % were aware that sharing razor blade or hair trimmer could be a means of transmitting viral pathogens like HCV and HBV. Similar trends of low awareness has been reported for pregnant women \[[@CR63]\]. Additionally, while the transmission dynamics of HCV remains varied and include unprotected sex, mother-to-child transmission and transfusion of infected blood, in many Ghanaian communities, there has been an over-emphasis on HCV and related viral hepatitis as sexually transmitted infections (STIs) \[[@CR13]\]. Such perceptions have often led to HCV-positive individuals been stigmatized and at times discouraged such patients seeking proper care to minimise their chances of spreading the disease.

Controlling HCV will require three (3) key strategies which include offering treatment for infected individuals, implementing measures to halt the transmission of the disease and reducing mortality arising from unmanaged complications such as HCC \[[@CR7]\]. Antiviral medications have shown great potency in curing HCV infections (approximately 90 % of infections) but access to these medicines remain poor in many developing countries including Ghana \[[@CR64]\]. To ensure that such therapies are available to majority of chronic HCV sufferers in Ghana, they must be provided freely under the country's National Health Insurance Scheme (NHIS). This must be one of the key focus or priority for the government considering that wider availability of highly effective new generation direct-acting antiviral medications to treat HCV infections would not only reduce the occurrence of complications such as HCC but will also lead to decline in prevalence of the disease arising from altered infectivity state of treated individuals.

Unfortunately, unlike HBV, a vaccine for HCV is currently unavailable and therefore interruption of infection transmission through risk reduction would rely mainly on education to improve knowledge and awareness of the transmission dynamics of the disease. While routine screening of the general population may not be recommended as it's deemed to be not cost effective, screening of high-risk groups such as injection drug users (IDUs) and persons with high-risk sexual behaviours should be expanded nationwide and provided possibly freely to increase patronage. This should be backed with other innovative strategies such as provision of comprehensive harm-reduction services to injection drug users including sterile injecting equipment \[[@CR64]\]. Additionally, attention needs to be paid to conditions in the prisons as the risk of HCV infection remains high in these settings. Agyei et al. \[[@CR38]\], reported that as much as 35.2 % of prisoners reported ever injecting drugs and of these 11.5 % were HIV-positive. Public health interventions should aim at addressing the specific needs of such populations as they may pose additional transmission risk once released into the community \[[@CR37], [@CR38]\].

Horizontal transmission of HCV has been recognized to be linked to factors such as age, socioeconomic/living conditions as well as other risky behaviours such as sharing towels, dental cleaning materials and chewing gum \[[@CR45]\]. Martinson et al. \[[@CR45]\], for instance, has demonstrated that general improvements in socio-economic conditions may lead to a decreased exposure to viral hepatitis including hepatitis B and HCV among Ghanaians. Over the last few decades, there have been significant improvement in the living conditions of Ghanaians. For instance, the percentage of Ghanaians with improved access to water increased from 56.0 % in 1990 to 86.0 % in 2012 \[[@CR65]\]. The proportion of Ghanaians classified as poor has also decreased by more than 50 % from 52.6 % in 1991 to 21.4 % in 2012 \[[@CR66]\]. Although, studies conducted after 2005 generally reported lower HCV prevalence than those conducted before, in the context of limited data it is difficult to assess the extent to which general improvements in socioeconomic conditions have contributed to reductions in the HCV burden across the country and for different regions. The high prevalence of HCV in Greater Accra may be due to the region's national status of harbouring the capital city. This has often resulted in a high influx of both young and old into its commercial areas from all corners of the country and internationally for business, tourism or to seek greener pastures, an atmosphere which provides a conducive environment for the promotion of anti-social behaviours such as drug abuse and prostitution; patterns which may facilitate HCV transmission \[[@CR67]\].

Although, limited studies have been conducted to evaluate the impact of chronic HCV infection on Ghana's health system and economy in general, the impact arising from the high prevalence of the disease may be enormous owing to significant mortality and costs associated with complications such as HCC and liver cirrhosis. The contribution of HCV to liver cirrhosis was demonstrated in a study by Blankson et al. \[[@CR37]\], which identified that chronic HCV infection was implicated in 1 in 14 liver cirrhosis cases. Treatment for chronic HCV is deemed to be expensive. A standard 12-week treatment with one of the newer drugs Sovaldi® (Sofosbuvir) cost around US \$ 84,000 which breaks down to \$1000 for each pill taken daily \[[@CR68]\]. This is certainly a cost that most HCV Ghanaians cannot afford neither could it be absorbed by any sustainable public funding. While generic versions of such medications cost significantly less, there remains major availability issues. The high prevalence of HCV infection in HIV patients is also likely to increase mortality in such groups. While majority of studies did not document the most prevalent age groups, high HCV burden is likely to impact on economic growth as productivity among affected persons are likely to be affected and their general wellbeing diminished. Thus, high HCV burden can have significant impact on Ghana's economy and as such a strong economic argument for government commitment and intervention in tackling the disease should be made.

Reducing the overall burden of chronic HCV infection in Ghana will require new measures and strategies and the recognition of the disease as one of the key country's priority areas. Recently, the World Health Organization (WHO) introduced updated guidelines as a framework for countries to plan the expansion of clinical services to persons suffering chronic HCV infection \[[@CR69]\]. The guideline highlights nine (9) key areas such as screening of high-risk, groups, mitigating liver damage through measures such as alcohol assessment and treatment with appropriate regimen such as interferon \[[@CR69]\]. The government of Ghana would need to pay closer attention to implementing the recommendations set out in this guideline if the battle against HCV is to be won. Tackling the burden of chronic HCV infection in Ghana would also require stronger commitments from government and all other interest groups with the objective of ensuring that measures to control HCV are fully incorporated in national policies. The role of civil societies and pressure groups in driving such changes have been widely recognized and their involvement in for instance, the fight against the HIV/AIDS epidemic has been referenced as a remarkable achievement including successfully pushing for the reduction in the cost of ARTs. The successes and experience from HIV/AIDS epidemic should guide future strategies against viral hepatitis such as HCV \[[@CR70]\].

Strengths and limitations {#Sec18}
-------------------------

The screening method employed can significantly impact on the HCV prevalence rate \[[@CR71]\]. Since our review covered a two decade period, the studies adopted different screening techniques there are likely vary in terms of sensitivity and specificity which could partly account for the difference in prevalence rates across studies published in different years. As indicated by Fox \[[@CR72]\], it can be extremely difficult to differentiate acute from chronic HCV infection especially in patients who have not previously undergone anti-HCV testing and it is possible that the prevalence rate reported in some studies may not be representative of only chronic infections. While this review highlights a growing evidence in this area of research as depicted by almost half (48 %) of studies were recently published (within last 5 years), there are significant regional variations. Nearly two-thirds (75 %) of studies as well as around 90 % of total population size involved were from two regions (Ashanti and Greater Accra), although these two regions represented just a little over 35 % of the country's population in 2010 \[[@CR73]\]. Also it was not possible to deduce aggregate HCV prevalence estimates for seven regions and no data was retrieved from the upper west region. A wider epidemiological study conducted around the same time may help to provide a more accurate prevalence estimate as well as minimize the wide heterogeneity as observed in the studies reviewed. Additionally, most studies involved adult participants with only one study specifically conducted in children \[[@CR45]\]. Likewise, most studies reported no information on HCV prevalence in relation to demographic (e.g. age and sex) and socio-economic (e.g. education) as well as risk profiles (e.g. blood transfusion, multiple injection drug use, HIV status) which are all known predictors of HCV status \[[@CR74]\]. It will be important for future research to look into the epidemiology of HCV in the underrepresented regions as well as targeted high-risk groups to provide greater insight into the HCV burden in Ghana. In spite of the above limitations, this review presents a more rigorous estimate of chronic HCV infection in Ghana that should inform health planning, policy decisions and the design of public health strategies by the ministry of Health and the Ghana Health service towards controlling the disease.

Conclusion {#Sec19}
==========

This study has documented a high prevalence of chronic HCV infection in Ghana. The results highlight the need for urgent public health interventions aimed at reducing the infection rate. These must include efforts to increase awareness and knowledge about HCV transmission dynamics, targeting the screening of high-risk groups and providing treatment for affected individuals. Further research is also needed to understand fully the population factors underlying this high HCV prevalence. New studies particularly in underrepresented regions and high-risk population groups are urgently needed to offer better perspective on the overall HCV burden in Ghana.
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